A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

June 19, 2022

Study Completion Date

July 8, 2022

Conditions

Prostatic NeoplasmsProstate NeoplasmsProstate Cancer

Interventions

DRUG

5-Azacitidine

subcutaneously on days 1-5 at a dose of 40 mg/m\^2

DRUG

all trans retinoic acid

45 mg/m\^2, will be taken orally on days 3-7 of each cycle, divided into two doses

DRUG

Lupron

7.5 mg x 1

Trial Locations (1)

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03572387 - A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment | Biotech Hunter | Biotech Hunter